The Duke Translational Research Institute’s mission is to rapidly and effectively invent, develop, and test new drugs, diagnostics, and devices for human use. DTRI, headed by Dr. Bruce Sullenger, provides guidance from experienced leadership, critical resources, and infrastructure for academic translational researchers.

DTRI Components

• Technology Cores
  • Biorepository and 'Omics'
  • Immune Monitoring and Vaccines
  • Cell and Tissue Therapies
  • Chemistry and Molecular Therapeutics
  • Imaging
  
• Translational Pilot Project Program
• North Carolina Research Campus and the MURDOCK Study

Collaborations between the 'bench' scientists and the clinical researchers of the Duke Clinical Research Institute will allow cross-analysis access to early phases of development in these areas to plan how to bring discoveries forward to be useful to patients.